Intelligence · Patents
Patents expiring in 2030
Annual patent cliff calendar for 2030 — US pharmaceutical patents by expiration date.
- Patents
- 880
Quick answer
880 indexed pharmaceutical patents have expiration dates in 2030. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 7846450
Melanoma associated peptide analogues and vaccines against melanoma
granted -
US 7846892
Compositions and methods for Alzheimer's disease
granted -
US 7846954
Heterocyclic derivatives as modulators of ion channels
granted -
US 7847084
VMP-like sequences of pathogenic Borrelia species and strains
granted -
US 7851631
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7850961
Methods for targeting solid tumor stem cells in a solid tumor using a notch4 receptor antagonist
granted -
US 7850970
Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
granted -
US 7851169
Compositions and methods for inhibiting squamous cell carcinoma
granted -
US 7851445
Angiogenic heparin-binding epitopes, peptide amphiphiles, self-assembled compositions and related methods of use
granted -
US 7851449
Peptide, pharmaceutical composition, and a method of treating microcirculation disorders
granted -
US 7851465
Compositions and methods relating to novel compounds and targets thereof
granted -
US 7851228
Methods for screening agents that modulate presenilin activity and A-β production
granted -
US 7851467
Carbamate compounds as 5-HT4 receptor agonists
granted -
US 7851473
Amide compound
granted -
US 7851480
Spiro 2,4-pyrimidinediamine compounds and their uses
granted -
US 7851506
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
granted -
US 7851565
Stabilized polymeric thiol reagents
granted -
US 7851632
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7851495
Thiophene-carboxamides useful as inhibitors of protein kinases
granted -
US 7851194
West Nile viruses with mutations in the 3′ terminal stem and loop secondary structure for use as live virus vaccines
granted -
US 7855214
Fused cyclic systems useful as inhibitors of TEC family protein kinases
granted -
US 7855220
Bicyclic derivatives as modulators of voltage gated ion channels
granted -
US 7855233
Citrate salt of Rasagiline
granted -
US 7855291
Process for the preparation of substituted phenylalanines
granted -
US 7855176
Reduced volume formulation of glatiramer acetate and methods of administration
granted -
US 7855076
Use of discoidin domain receptor 1 (DDR1) and agents that affect the DDR1/collagen pathway
granted -
US 7855190
Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
granted -
US 7854932
Immunogenic compositions comprising progastrin and uses thereof
granted -
US 7855202
Imidazopyridine derivatives as A2B adenosine receptor antagonists
granted -
US 7855221
Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
granted -
US 7855276
Framework residue substituted humanized COL-1 antibodies and their use
granted -
US 7855191
Agent having a destructive effect on malignant tumors and method for the production thereof
granted -
US 7858797
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7858792
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7858123
Inorganic materials for hemostatic modulation and therapeutic wound healing
granted -
US 7858592
Interfering RNAs against the promoter region of P53
granted -
US 7858349
Anti-cancer compounds
granted -
US 7858583
Process for purifying glycopeptide phosphonate derivatives
granted -
US 7858605
Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
granted -
US 7858633
Cycloalkyl substituted pyrimidinediamine compounds and their uses
granted -
US 7858635
Spiro compounds as modulators of muscarinic receptors
granted -
US 7858749
Polymer-factor VIII moiety conjugates
granted -
US 7858786
Pyrimidines and pyrazines useful as modulators of ion channels
granted -
US 7858790
Modulators of muscarinic receptors
granted -
US 7858795
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7858657
Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
granted -
US 7863415
Amino acid and peptide conjugates of amiloride and methods of use thereof
granted -
US 7863421
Polymer-factor VIII moiety conjugates
granted
Frequently asked questions
How many pharma patents expire in 2030?
880 published patents in our USPTO index have expiration dates falling in calendar year 2030.